Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arun A Azad

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
BMC Medicine|March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancerBlossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
The Lancet. Oncology|October 21, 2025
Lutetium-177 [<sup>177</sup>Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trialLouise Kostos, James P Buteau, Jing Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancerAslı D Munzur, Cameron Herberts, Edmond M Kwan, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Cancer Discovery|July 2, 2026
Germline CDK12 variants in aggressive prostate cancerSofie H Tolmeijer, Corinne Maurice-Dror, Shahneen Sandhu, et al.
Nature Communications|August 20, 2021
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncologyGail P Risbridger, Ashlee K Clark, Laura H Porter, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
BMC Medicine|March 25, 2022
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancerBlossom Mak, Hui-Ming Lin, Edmond M Kwan, et al.
The Lancet. Oncology|October 21, 2025
Lutetium-177 [<sup>177</sup>Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trialLouise Kostos, James P Buteau, Jing Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 6, 2026
Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancerAslı D Munzur, Cameron Herberts, Edmond M Kwan, et al.
Ebiomedicine|October 17, 2021
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinaseHui-Ming Lin, Blossom Mak, Nicole Yeung, et al.
The Lancet. Oncology|July 5, 2025
First-in-human results of terbium-161 [<sup>161</sup>Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 studyJames P Buteau, Louise Kostos, Price A Jackson, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Cancer Discovery|July 2, 2026
Germline CDK12 variants in aggressive prostate cancerSofie H Tolmeijer, Corinne Maurice-Dror, Shahneen Sandhu, et al.
Nature Communications|August 20, 2021
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncologyGail P Risbridger, Ashlee K Clark, Laura H Porter, et al.
Pageof 14